Neumora Therapeutics, Inc. Common Stock
Neumora Therapeutics, Inc. Common Stock (NMRA) SEC Filings & 10-K Annual Reports
SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.
SEC EDGAR · data.sec.gov · CIK 0001885522 · NMRA · NASDAQ · as of Jun 8, 2026
Filing snapshot
Source: SEC EDGAR (data.sec.gov) · CIK 0001885522 · Updated hourly · Not investment advice
Latest Annual Report
Latest Key Filings
Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.
SEC Filing History
About SEC Filings & 10-K Annual Reports
Neumora Therapeutics, Inc. Common Stock (NASDAQ: NMRA) has submitted 242 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2023. As a Healthcare sector company with CIK 0001885522, all filings are publicly accessible via the EDGAR database at no cost.
The annual 10-K report is Neumora Therapeutics, Inc. Common Stock's most comprehensive regulatory disclosure. The most recent Neumora Therapeutics, Inc. Common Stock 10-K was filed on 2026-03-30 for fiscal year ending 2026. Historical NMRA 10-K annual reports are available from 2021 through 2026.
Investors researching Neumora Therapeutics, Inc. Common Stock SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.
Frequently Asked Questions
NMRA SEC Filings · 8 questionsNeumora Therapeutics, Inc. Common Stock (NMRA) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 242 filings and access original documents at no cost. Neumora Therapeutics, Inc. Common Stock's CIK is 0001885522.